- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02081677
One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers
18. června 2018 aktualizováno: Johnson & Johnson Vision Care, Inc.
One Month Daily Wear Clinical Evaluation of Three Prototype Soft Contact Lenses in a Population of Habitual and Neophyte Contact Lens Wearers
There will be four study lenses tested; one marketed lens, and three prototype study lenses.
Subjects will be randomized to one of the four study lenses which will be worn in a daily wear modality, with a two week replacement.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
80
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indie, 600 006
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 39 let (Dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- The subject must be between 18 and 39 years of age.
- The subject must be able to read and understand English.
- The subject read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
- The subject must not have been a participant in a contact lens or contact lens solution study/investigation in the previous seven days.
- The subject must be willing to wearthe study lenses for at least 6 hours per day, 7 days per week (e.g. does not regularly swim).
- The subject must appear able and willing and able to the adhere to the instructions set forth in this clinical protocol.
- The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -4.00D in each eye.
- The subject's refractive astigamatism must be less than or equal to -1.00D in both eyes.
- The subjet must have best corrected visual acuity of 20/30 (6/9 or +0.20 logMAR) or better in each eye.
- The subject must require a visual correction in both eyes (no monofit or monovision allowed).
The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No amblyopia
- No evidence of lid abnormality or infection (including blepharitis/meibomitis)
- No conjunctival abnormality or infection.
- No clinically significant slit lamp findings (i.e. stromal edema, vascularization, corneal scaring, infiltrates or abnormal opacities).
- No other active ocular diseases.
Exclusion Criteria:
- Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Any systemic diseases, autoimmune disease, or use of medication, which may interfere with contact lens wear.
- Clinically significant (Grade 3 or 4) corneal edeam, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid permeable contact lens wear.
- Pregnancy or lactation (subjects who become pregnant during the study will be discontinued).
- No extended wear in the last 3 months.
- Diabetes.
- Infectious diseases (e.g. hepatitis, tuberculosis) or immunosuppressive disease (e.g. HIV).
- Has had refractive surgery.
- Employee of VRF with direct involvement in the study or a family member of the clinic.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: etafilcon A
Marketed control soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
|
|
Experimentální: Prototype E1
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Ostatní jména:
|
|
Experimentální: Prototype E2
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Ostatní jména:
|
|
Experimentální: Prototype E3
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Corneal Staining (Area)
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Staining Area was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 11-point scale (i.e.
Grade 0= 0% of region covered, Grade 1 =10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4= 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered,Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered and Grade 10 = 100% of region covered).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Depth)
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Staining Depth was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 4-point scale (i.e.
Grade 0= None, Grade 1 =Superficial epithelial, Grade 2 = Full epithelial, Grade 3 =stromal glow).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Type)
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Staining was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 5-point scale (i.e.
Grade 0= None, Grade 1 =Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate and Grade 4 = Patch (greater or equal to 1mm).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Limbal Conjunctival Redness
Časové okno: Baseline and 2-Week Follow-up
|
Limbal Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Limbal Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for limbal redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Bulbar Conjunctival Redness
Časové okno: Baseline and 2-Week Follow-up
|
Bulbar Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Bulbar Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for bulbar redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Visual Acuity (LogMAR)
Časové okno: 4-Week Follow-up
|
Visual Acuity (LogMAR) was assessed bionocularly at the 4-week follow-up evaluations.
The average visual acuity (LogMAR) for each lens was reported.
|
4-Week Follow-up
|
|
Lens Fitting Characteristics
Časové okno: Post Lens Fitting and 4-Week Follow-up
|
Lens fit was assessed for each subject eye at post lens fitting and 4- week follow-up evaluations.
Lens fit is a binary response as acceptable or unacceptable lens fit.
The percentage of eyes with acceptable lens fit was reported.
|
Post Lens Fitting and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Burning/Stinging)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Burning/Stinging was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Corneal Edema
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Edema was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Conjunctival Injection
Časové okno: Baseline and 4-Week Follow-up
|
Conjunctival Injection was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Neovascularization
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Neovascularization was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining
Časové okno: Baseline and 4-Week Follow-up
|
Corneal Staining was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Tarsal Abnormalities
Časové okno: 1-, 2- and 4-Week Follow-up
|
Tarsal abnormalities were assessed using a biomicroscope at baseline, post lens fitting, 1-, 2- and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0, 1, 2, 3 and 4) with grade 0 represents the absence of abnormalities and 1 to 4 representing successively worse abnormalities (i.e.
Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The percentage of eyes with Grade 3 or higher was reported.
|
1-, 2- and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Cloudy/Blurry/Hazy)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Cloudy/Blurry/Hazy was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Dryness)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Dryness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Grittiness/Foreign Body Sensation)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Grittiness/Foreign Body Sensation was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Irritation/Discomfort)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Irritation/Discomfort was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Itchiness/Scratchiness)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Itchiness/Scratchiness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Lens Awareness)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Lens awareness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Redness)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Redness wasassessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Variable Vision)
Časové okno: Baseline and 4-Week Follow-up
|
The Ocular symptom Variable Vision was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
6. února 2014
Primární dokončení (Aktuální)
25. června 2014
Dokončení studie (Aktuální)
25. června 2014
Termíny zápisu do studia
První předloženo
5. března 2014
První předloženo, které splnilo kritéria kontroly kvality
6. března 2014
První zveřejněno (Odhad)
7. března 2014
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
19. června 2018
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
18. června 2018
Naposledy ověřeno
1. července 2017
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- CR-5146
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ano
produkt vyrobený a vyvážený z USA
Ano
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .